Suppr超能文献

中国哮喘的患病率和残疾调整生命年率:来自 2019 年 G20 全球疾病负担研究的结果。

Prevalence and Disability-Adjusted Life Year Rates of Asthma in China: Findings from the GBD Study 2019 of the G20.

机构信息

Department of Allergy and Clinical Immunology, Department of Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China.

School of Social Sciences, Main Campus, Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia.

出版信息

Int J Environ Res Public Health. 2022 Nov 8;19(22):14663. doi: 10.3390/ijerph192214663.

Abstract

BACKGROUND

The credible materials about the burden of asthma in China when compared to other countries in the group of twenty (G20) remain unavailable.

OBJECTIVES AND DESIGN

Following the popular analysis strategy used in the Global Burden of Disease Study, the age-, sex-, country-specific prevalence, and disability-adjusted life years (DALYs) of asthma in China were analyzed. Meanwhile, the comparison in trends between China and other countries in the G20 was also evaluated.

RESULTS

In 2019, asthma was the 8th leading cause of the DALYs' burden of 369 diseases in China. From 1990 to 2019, the age-standardized prevalence and DALY rates of asthma in China decreased by 14% and 51%, respectively; further, the decline rate of DALYs was much higher than the global average (-51%: -43%). It is worth noting that the overall population age-standardized DALYs rate of asthma in China was the lowest in the G20 during 2019 (102.81, 95% UI: (72.30,147.42)/100,000). Moreover, the age-standardized asthma prevalence rate peaks in both childhood (178.14, 95% UI: (90.50, 329.01)/100,000) and the elderly (541.80, 95% UI: (397.79, 679.92)/100,000). Moreover, throughout the study, subjects in the 5 to 9 years old interval were a constant focus of our attention.

CONCLUSIONS

The disease burden of asthma has varied greatly by gender and age over the past 30 years. In contrast to the increasing burden in most other G20 countries, the age-standardized prevalence rate of asthma shows a significant decreasing trend in China, however, the age-standardized DALYs rate shows a fluctuating change, and has even shown a rebound trend in recent years.

摘要

背景

与二十国集团(G20)中的其他国家相比,中国哮喘负担的可靠数据仍然缺乏。

目的和设计

采用全球疾病负担研究中流行的分析策略,分析了中国哮喘的年龄、性别、国家特异性患病率和伤残调整生命年(DALYs)。同时,还评估了中国与 G20 中其他国家的趋势比较。

结果

2019 年,哮喘是中国 369 种疾病导致 DALYs 负担的第 8 大原因。1990 年至 2019 年,中国哮喘的年龄标准化患病率和 DALY 率分别下降了 14%和 51%;此外,DALYs 的下降速度远高于全球平均水平(-51%:-43%)。值得注意的是,2019 年中国 G20 国家总体人口年龄标准化 DALYs 率最低(102.81,95%置信区间(72.30,147.42)/100000)。此外,年龄标准化哮喘患病率在儿童期(178.14,95%置信区间(90.50,329.01)/100000)和老年期(541.80,95%置信区间(397.79,679.92)/100000)均达到峰值。此外,在整个研究过程中,5 至 9 岁年龄段的人群一直是我们关注的焦点。

结论

过去 30 年来,哮喘的疾病负担在性别和年龄上有很大差异。与大多数其他 G20 国家负担增加的情况相反,中国哮喘的年龄标准化患病率呈显著下降趋势,然而,年龄标准化 DALYs 率呈波动变化,近年来甚至出现反弹趋势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78c/9690014/8f67236211dd/ijerph-19-14663-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验